Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 30;5(22):11133-42.
doi: 10.18632/oncotarget.2563.

The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal

Cathy Eng  1 , George J Chang  2 , Y Nancy You  2 , Prajnan Das  3 , Miguel Rodriguez-Bigas  2 , Yan Xing  2 , Jean-Nicolas Vauthey  2 , Jane E Rogers  4 , Aki Ohinata  1 , Priyanka Pathak  1 , Salil Sethi  1 , Jonathan K Phillips  1 , Christopher H Crane  3 , Robert A Wolff  1
Affiliations

The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal

Cathy Eng et al. Oncotarget. .

Abstract

Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists. To determine the best approach, all patients diagnosed with metastatic SCCA of the anal canal treated at a single institution were evaluated for choice of chemotherapy and treatment outcome. A retrospective study from January 2000 to May 2012 was conducted. Electronic medical records were reviewed for diagnosis of metastatic SCCA of the anal canal. All patients were treatment naïve for metastatic disease and completed all radiographic imaging at our institution. The purpose of this study was to evaluate outcomes among patients who received systemic chemotherapy and if appropriate were referred for multidisciplinary intervention (e.g., surgery, radiofrequency ablation, etc.). Seventy-seven patients fulfilled eligibility criteria. Forty-two patients (55%) received 5-fluorouracil (5-FU) + cisplatin (PF); 24 patients (31%) received carboplatin + paclitaxel (CP); 11 patients (14%) received an alternative regimen. After a median follow-up of 42 months, the median progression-free survival (PFS) for all patients was 7 months; the median overall survival (OS) was 22 months. Thirty-three patients (43%) underwent multidisciplinary management for metastatic disease resulting in a median PFS of 16 months (95% CI: 9.2 -22.8) and median OS of 53 months (95% CI: 28.3 - 77.6). Systemic chemotherapy provides durable survival for patients with surgically unresectable metastatic SCCA of the anal canal. Multidisciplinary management for select patients with metastatic disease effectively improves survival and should be considered whenever possible.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors disclose no conflicts of interest.

Figures

Figure 1
Figure 1. Median Overall Survival of All Treated Patients
Figure 2
Figure 2. Median Overall Survival of Patients Treated with Multidisciplinary Intervention versus Palliative Systemic Chemotherapy
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
    1. Boman BM, Moertel CG, O'Connell MJ, Scott M, Weiland LH, Beart RW, Gunderson LL, Spencer RJ. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984;54:114–125. - PubMed
    1. Eng C, Abbruzzese J, Minsky BD. Chemotherapy and radiation of anal canal cancer: the first approach. Surg Oncol Clin N Am. 2004;13:309–320. viii. - PubMed
    1. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–4351. - PMC - PubMed
    1. Sebag-Montefiore D, James R, Meadows H, Begum R, Cunningham D, Northover J, Ledermann J. The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial. J Clin Oncol. 2012;30

Publication types

MeSH terms

Supplementary concepts